UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington,  D.C. 20549 

 

FORM 8-K



CURRENT REPORT 

 Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934




Date of Report (Date of earliest event reported): November 26, 2007

CYCLACEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter) 


Delaware

(State or other jurisdiction of incorporation)


  
     
     
     
  
  
    0-50626

    (Commission File Number) 
     
    91-1707622

      (IRS Employer Identification No.)
  
  
     
     
     
  
  
    200 Connell Drive

Suite 1500
    

    Berkeley Heights, NJ 07922


    (Address of principal executive offices and zip code) 
  



(908) 517-7330

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)


 


Check the appropriate box below if the Form 8-K  filing is intended to simultaneously satisfy the filing obligation of the  registrant under any of the following provisions (see General  Instruction A.2. below): 



    o
     
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



     


    o
     
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



     


    o
     
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



     


    o
     
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 
 
 








Item 8.01 Other Events.
Attached as Exhibit 99.1 is a copy of a press release issued by Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the “Company”), dated November 26, 2007, providing an overview of recent advances in its clinical development stage programs and announcing its 2008 key business objectives for such programs. 
Item 9.01 Financial Statements and Exhibits 
(d) Exhibits 
 


 
        
                        
Number
 
        
                        
 
 
        
                        
Description 
  
 
        
                        
99.1
 
        
                        
 
 
        
                        
Press release, dated November 26, 2007
  

 
 




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 
 


 
        
                        
 
 
        
                        
 
 
        
                        
 
 
        
                        
CYCLACEL PHARMACEUTICALS, INC.
  
 
        
                        
 
 
        
                        
  
 
        
                        
 
 
        
      
By: 
 
        
                        

 /s/ Paul McBarron
  
 
        
                        
 
 
        
                        
 
 
        
                        
 
 
        
                        
Name: 
 
        
                        
Paul McBarron
  
 
        
                        
 
 
        
                        
 
 
        
                        
 
 
        
                        
Title: 
 
        
                        
Executive Vice President—Finance and 
 Chief Operating Officer
  
 
        
                        
Date: November 27, 2007
 
        
                        
 
 
        
                        
 
 
        
                        
 
  

 
 




EXHIBIT INDEX 
 


 
        
                        
Exhibit
            
No
 
        
                        
 
 
        
                        
Description
  
 
        
                        
99.1
 
        
                        
 
 
        
                        
Press Release, dated November 26, 2007